Information Provided By:
Fly News Breaks for March 3, 2020
Mar 3, 2020 | 08:54 EDT
Canaccord analyst Arlinda Lee raised the firm's price target on Karyopharm to $35 from $22 and keeps a Buy rating on the shares. The analyst cited the positive topline results from its pivotal, randomized open label BOSTON trial in 2-4L myeloma. the price target increase is a reflection of longer duration of treatment in myeloma.